Posted by Michael Wonder on 24 Aug 2023
Soliris approved in Japan for paediatric patients with generalised myasthenia gravis
24 August 2023 - Soliris reduced disease severity and symptoms with sustained improvements over 26 weeks in Phase III clinical trial.
Soliris (eculizumab) has been approved in Japan for expanded use to include the treatment of generalised myasthenia gravis in paediatric patients who are anti-acetylcholine receptor antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin therapy or plasmapheresis.
